We Didn’t Borrow the Science. We Built It.

What it really takes to bring a clinically validated supplement to market and why we refused to take the easy road.

The global dietary supplements market is on track to be worth $230 billion by 2026. Walk into any health store or scroll through your social media feed for more than five minutes and you will see hundreds of products promising to “boost focus,” “enhance clarity,” or “support cognitive performance.”

Most of them are lying to you. Not maliciously, perhaps. But the industry has a quiet, widely accepted practice I call “borrowed science.”

Here is how it works: a company identifies ingredients that showed promise in a study somewhere, at some point. They combine them into a formula, put it in a nice bottle, and go to market. They never test the finished product. They never run a clinical trial. They assume that if Ingredient A is good and Ingredient B is good, the result must be great.

That assumption is, at best, a guess. And at Numin, we refused to build our company on a guess.

Why This Became Personal for Me

I have spent the better part of two decades at the intersection of clinical research and operational strategy. I have guided global brands through clinical development pathways. I have seen what rigorous evidence looks like and what it does not look like. So when I joined Senescence Life Sciences and we began developing Numin, I knew from day one that there was only one path I was willing to take.

We were going to test the finished product. We were going to run a proper clinical trial. And we were going to get it published in a peer-reviewed journal.

That decision set us on a path that took years. And it was worth every single step.

“When clinical rigour meets innovative strategic scale, we do more than just launch a product. We equip people with a biological foundation that is proven to work.”

The Invisible Work Nobody Tells You About

If you have ever wondered why more supplement companies do not run clinical trials, it is not because they have not thought of it. It is because it is enormously difficult.

In the pharmaceutical world, bringing a single drug to market can take 8 to 12 years and cost upwards of $2 billion. Our timeline and investment were far smaller but the rigour of the process is not. Clinical research is slow. It is expensive. It is unforgiving. And when you are a small, science-first biotech company, the pressure to cut corners and get to market faster is very real.

We did not cut corners.

What we did instead was spend years on the work that nobody sees.

We spent a long time perfecting the formulation. Numin’s fuel stack, including Methylsulfonylmethane, L-Tyrosine, Rhodiolife®, TurmiPure Gold®, and Chromium Picolinate, was not assembled overnight. Each ingredient was selected based on its hypothesised mechanism of action and its potential to support neuronal health.

We designed a study that would actually prove something. Our randomised, double-blind, placebo-controlled crossover trial was not chosen because it was easy. It was chosen because it is the gold standard of clinical research design. In this design, each participant acts as their own control, which dramatically increases statistical power. Nothing is assumed. Everything is tested.

We chose the right environment. We tested Numin in a real-world, high-pressure context: competitive video gaming. League of Legends players face thousands of rapid decisions over a 13-hour gaming session. If there was ever a setting that would stress-test the limits of human cognitive function and reveal whether Numin made a measurable difference, this was it.

What We Found

The results were published in Frontiers in Nutrition in 2025, a peer-reviewed, internationally recognised journal. That publication process is not a formality. Every manuscript undergoes rigorous scrutiny by independent scientific experts. Rejection rates are high. You either meet the standard or you do not.

We met the standard.

Win rates increased by 4.5% in the Numin group versus a 0.6% decline in the placebo group, a statistically significant result. The Numin group maintained consistent gameplay behaviours throughout the day, including communication with teammates and in-game decision sequences, while the placebo group showed significant declines in both. Mouse input patterns in the Numin group indicated more deliberate, attentive behaviour, while the placebo group showed more erratic movements, a measurable physical sign of cognitive fatigue setting in.

None of those results are marketing language. They are published, peer-reviewed scientific findings. That is a distinction that matters enormously.

“We did not just want to be another bottle on the shelf. We wanted to be a category of one.”

What “Clinically Validated” Actually Means

I want to be honest about something, because I think integrity in communication is as important as integrity in research.

Our study is a pilot study. The sample size was 23 participants, appropriate for a well-powered crossover design, but not a large-scale trial. Some of our cognitive measures, including the Decision Fatigue Scale scores, showed trends in the right direction but did not reach statistical significance. We acknowledge this in the published paper, because that is what honest science looks like.

What we can say, with confidence, is this: the objective, real-world performance metrics, the ones that are hardest to fake and most meaningful in practice, showed clear, statistically significant improvements in the Numin group. And those results were good enough to be accepted by one of the world’s most rigorous nutrition journals.

That is the foundation we are building on. Not the ceiling.

Why This Matters to You

Whether you are a supplement enthusiast trying to make informed choices, a working professional managing a relentless cognitive load, or someone building a company and wondering whether clinical validation is worth the investment, the answer from where I am standing is the same.

It is always worth it.

Because the alternative, asking people to trust a product that has not been tested, is something I was not willing to do. Not because of regulation or liability. Because of respect. For the science, for the process, and for the people who are going to put this in their bodies every day.

The next time you pick up a supplement, ask one question: did they test the finished product?

If the answer is no, you are not buying science. You are buying a story.

We built something different. And we have the data to prove it.